COPD stories

Oct 2, 2026

TTHealthWatch podcast covers new treatment target for asthma and COPD

The weekly podcast from Texas Tech University features discussion of a new therapeutic target for asthma and chronic obstructive pulmonary disease, along with other top medical stories. The podcast is co-hosted by Elizabeth Tracey of Johns Hopkins Medicine and Dr. Rick Lange of Texas Tech Health El Paso.

Oct 2, 20263 sources

Sep 8, 2026

AstraZeneca lung disease drug shows 30% reduction in COPD exacerbations

AstraZeneca announced its experimental drug tozorakimab achieved approximately 30% reductions in moderate and severe COPD exacerbations compared to standard therapy in two late-stage studies presented at the European Respiratory Society Congress.

Sep 8, 20263 sources

Top claims

▪The purinergic 2X3 receptor antagonists gefapixant, BLU-5937, and sivopixant (S-600918) are targeted therapies under development for refractory chronic cough.
▪A phase I trial evaluated ARO-RAGE, an inhaled, targeted, small interfering RNA therapy that targets the receptor for advanced glycation end products (RAGE) in pulmonary inflammation.
▪Kenney Blewett's pulmonologist prescribed a new chronic obstructive pulmonary disease medication on June 2, 2026, which Walgreens delayed due to an insurance issue.

Subtopics

Asthma1 Clinical trials1 Drug Approval and Clinical Trials1 Drug Policy, Pricing & Approval1 Medical research1 Pharma1 Respiratory diseases1

Related timelines